Tipsheet
What matters at India’s listed companies
Earnings · Pharmaceuticals · Small cap

NGL Fine-Chem profit surges 128% as Indian revenue doubles

Consolidated profit jumped to ₹48.13 crore on 36% revenue growth, driven by a more-than-doubling of Indian operations.

4 earlier stories on NGL Fine-Chem Ltd.
Mkt cap₹1,847 cr
P/E38.38×
ROE7.39%
Debt / eq.0.27
Div yld0.06%
128% Year-on-year jump in consolidated net profit.

What's new

  • FY26 consolidated profit surged 128% to ₹48.13 cr on 36% revenue growth to ₹500.95 cr.
  • Indian revenue more than doubled to ₹157.90 cr, becoming the fastest-growing geographic segment.
  • Final dividend maintained at ₹1.75 per share; auditors issued a clean opinion.

Why this matters

The gap between 36% revenue growth and 128% profit growth signals significant operating leverage as the company scales. The sharp acceleration in the Indian market, which now contributes about 32% of consolidated revenue, shifts the company's geographic risk and growth profile.

What we're watching

  • Whether the 128% profit growth is repeatable or a one-time margin expansion event.
  • The sustainability of the hyper-growth in Indian operations versus more mature overseas markets.
  • The board's capital allocation, as it retained the dividend despite tripling its profit.

The full read

NGL Fine-Chem's FY26 results are a story of scaling profitability. Revenue climbed 36% to ₹500.95 crore. Net profit ballooned 128% to ₹48.13 crore. The gap is the headline. It points to costs not growing in line with sales as the company expands. The geographic split is the most striking detail. Indian operations more than doubled to ₹157.90 crore, growing faster than the rest-of-world segment, which jumped 78% to ₹190.94 crore. Asia Pacific grew a more modest 28%. The board maintained the dividend at ₹1.75 per share, retaining cash rather than passing through the full profit increase. A clean audit closes the books on a strong year. The key number is not the revenue growth. It is the profit margin expanding as the company scales in its home market.

Questions answered

How did profit growth outpace revenue growth so dramatically?
Net profit grew 128% on 36% revenue growth, indicating costs did not rise in line with sales. The specific drivers aren't detailed, but the geographic expansion, especially the doubling of Indian revenue, likely contributed to better cost absorption.
Which markets drove the overall revenue increase?
India led with revenue more than doubling to ₹157.90 crore. Rest-of-world sales jumped 78% to ₹190.94 crore, and Asia Pacific grew 28% to ₹144.45 crore.
What was the dividend decision?
The board recommended a final dividend of ₹1.75 per share, unchanged from the prior year. Despite the strong profit growth, the payout was not increased.
Were there any qualifications in the audit?
No. The auditors issued an unmodified opinion on the results, which is a clean sign-off with no reservations.
Mentioned: NGL Fine-Chem Ltd. · ₹500.95 cr consolidated revenue · ₹48.13 cr net profit
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

NGL Fine-Chem Ltd.

Pharmaceuticals
₹1,668 cr
P/E 34.67×

Latest quarter · Mar 2026

Sales₹149 cr
Net profit₹13 cr
Op. margin+14.3%
EPS₹21.83

Strength & growth

Debt / equity0.27×
Current ratio1.98×
Sales CAGR+17.9%
EPS CAGR+15.1%
  1. 21 May 2026 · 9:21 PM IST NGL Fine-Chem profit surges 128% as Indian revenue doubles
  2. 51d ago NGL Fine-Chem profit jumps 128% as India revenue more than doubles
  3. 51d ago NGL Fine-Chem profit more than doubles to ₹48 cr on broad-based demand
  4. 52d ago NGL Fine-Chem profit jumps 128% on strong domestic and export demand
  5. 52d ago NGL Fine-Chem profit surges 128% on broad geographic growth